John Parkinson

In this episode, clinicians discuss challenges associated with these topics and offer some insights on them.

Expert discussion of several topics including diagnosis, clinical management in older adults, multidrug resistance, and long-acting injectables and PrEP.

The third and final episode in our series looks at what is in the pipeline as well as a discussion around FDA guidance.

The second episode in our series looks to address clinical management in a time when antimicrobial resistance appears to be growing.

This series looks to discuss several topics around these infections including diagnosis, treatment, challenges in managing UTIs in patients with dementia and neurogenic bladders, antibiotic resistance, and considerations for patients and caregiver engagement.

As a potential alternative to antibiotic treatments, this investigational immunization offered protection for several years.

The FDA has issued a Complete Response Letter for the New Drug Application of cefepime-taniborbactam, requesting additional chemistry, manufacturing, and controls data.

The panel discusses the importance of discussing the immunizations with patients now, as well as the value of them in future seasons.

Last year’s historic RSV season left many wondering if this was going to become a recurring trend. Physicians weigh in on what they are seeing at their institutions in terms of infection rates.

The federal agency says infants of a certain age should receive this monoclonal antibody to protect against the virus.

From a virus that had no treatment options, to one that may be prevented in two different modalities, clinicians are hoping to see a reduction in respiratory syncytial virus (RSV) incidence rates, starting this fall.

With an FDA approval, it would be the first new class of oral antibiotics for uncomplicated urinary tract infections (uUTI) in over 20 years.

The patient, referred to as the “New York patient,” was treated with stem cells from cord blood, and has remained HIV-free in her blood since her transplant in 2017.

The new guidance is the first update since 2008, replacing the previous risk-based recommendations.

The therapy, bepirovirsen, is an antisense oligonucleotide that targets all Hepatitis B (HBV) messenger RNAs, and the company is hoping it will become a functional cure.

The federal agency set a Prescription Drug User Fee Act (PDUFA) action date of August 2023.

Results reported at CROI showed that 2 cohorts of the ongoing, phase 3 DELIVER study that this form of PrEP modality posed no differences in pregnancy and infant outcomes.